Tempest Therapeutics, Inc. (TPST)
Nasdaq · Healthcare · Biotechnology
$0.7926−2.29%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.4M
- 52-week range
- $0.743 – $12.23
- 52-week change
- −92.45%
- EPS (trailing)
- −$3.93
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$26.3M
- Diluted EPS
- −$6.33
- Free cash flow
- −$26.8M
From the company’s annual report on SEC EDGAR.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Headquarters: Brisbane, United States · 4 employees · tempesttx.com